Skip to main content
Equibles
TARS logo

TARS · Tarsus Pharmaceuticals, Inc. · Analyst Estimates

Track TARS — free

Use TARS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TARS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$71.74 +0.98 (+1.38%) Q2 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$3.15B
Shares
43.88M
Volume · Oct 28 110.22K Avg daily vol (3M) 843.45K

Analyst Estimates

Compare analyst forecasts for Tarsus Pharmaceuticals, Inc. across metrics and forecast periods.

Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.

Compiled consensus

These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.

Captured 2026-10-22 01:19 UTC · Publication dates shown per estimate · 8 metric / period groups

FY ending 2026-12-31

Analyst estimates for FY ending 2026-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
-11.63
-5.79
-2.52
3
-5.67
-2.10
-2.13
-2.25
0
0
0
0
Revenue
USD
Publication date not stated
722.40M
736.88M
753.66M
5
 — — — — — — — —

FY ending 2027-12-31

Analyst estimates for FY ending 2027-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
-1.59
-0.50
1.04
3
-0.36
2.42
2.33
1.66
0
0
0
0
Revenue
USD
Publication date not stated
890.00M
920.04M
958.28M
4
 — — — — — — — —

Q ending 2026-09-30

Analyst estimates for Q ending 2026-09-30
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
-2.01
-1.77
-1.46
3
-1.69
-1.54
-1.53
-1.84
0
0
0
0
Revenue
USD
Publication date not stated
181.20M
190.78M
195.17M
5
 — — — — — — — —

Q ending 2026-12-31

Analyst estimates for Q ending 2026-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
-9.57
-4.82
-0.07
2
-4.78
0.00
-0.044
-0.065
0
0
0
0
Revenue
USD
Publication date not stated
205.24M
210.89M
222.53M
4
 — — — — — — — —
Key facts CIK 1819790 CUSIP 87650L103 13F (30d) 33 filings 33 filers Visit website Investor relations